PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
15455375-1	2005	Several oncogenes isolated by the NIH/3T3 transformation assay, i.e., dbl, dbs, lbc, lfc, lsc, net, ost and tim, contain a Dbl homology (DH) and a pleckstrin-homology (PH) domain and act as GEFs (guanine nucleotide exchange factors) for Rho-like GTPases.	dbs	75-78	MCF.2 cell line derived transforming sequence	Homo sapiens	123-126
15199069-5	2004	However, this relative orientation is dissimilar to Dbs in the Dbs/Cdc42 structure.	dbs	52-55	cell division cycle 42	Homo sapiens	67-72
14991610-0	2004	The RhoA- and CDC42-specific exchange factor Dbs promotes expansion of immature thymocytes and deletion of double-positive and single-positive thymocytes.	dbs	45-48	ras homolog family member A	Mus musculus	4-9
14991610-0	2004	The RhoA- and CDC42-specific exchange factor Dbs promotes expansion of immature thymocytes and deletion of double-positive and single-positive thymocytes.	dbs	45-48	cell division cycle 42	Mus musculus	14-19
14991610-2	2004	Dbs is a guanine nucleotide exchange factor which is expressed throughout thymocyte development and is able to activate the Rho family GTPases CDC42, RhoA and RhoG.	dbs	0-3	cell division cycle 42	Mus musculus	143-148
14991610-2	2004	Dbs is a guanine nucleotide exchange factor which is expressed throughout thymocyte development and is able to activate the Rho family GTPases CDC42, RhoA and RhoG.	dbs	0-3	ras homolog family member A	Mus musculus	150-154
14991610-2	2004	Dbs is a guanine nucleotide exchange factor which is expressed throughout thymocyte development and is able to activate the Rho family GTPases CDC42, RhoA and RhoG.	dbs	0-3	ras homolog family member G	Mus musculus	159-163
12215546-6	2002	Guided by this information, we mutated Dbs to alter significantly its relative exchange activity for RhoA versus Cdc42 and show that the transformation potential of Dbs correlates with exchange on RhoA but not Cdc42.	dbs	165-168	ras homolog family member A	Mus musculus	197-201
12856495-4	2003	Nevertheless, it is important for neurosurgeons to be aware of TMS, because findings from TMS studies will have implications for neurosurgical approaches like DBS and VNS.	dbs	159-162	PYD and CARD domain containing	Homo sapiens	63-66
12856495-4	2003	Nevertheless, it is important for neurosurgeons to be aware of TMS, because findings from TMS studies will have implications for neurosurgical approaches like DBS and VNS.	dbs	159-162	PYD and CARD domain containing	Homo sapiens	90-93
12376551-5	2002	Vav2 (which activates RhoA, Rac1, and Cdc42) and to a lesser degree Dbs (which activates RhoA and Cdc42) activated RhoG in vitro.	dbs	68-71	ras homolog family member A	Homo sapiens	89-93
12376551-5	2002	Vav2 (which activates RhoA, Rac1, and Cdc42) and to a lesser degree Dbs (which activates RhoA and Cdc42) activated RhoG in vitro.	dbs	68-71	cell division cycle 42	Homo sapiens	98-103
12376551-5	2002	Vav2 (which activates RhoA, Rac1, and Cdc42) and to a lesser degree Dbs (which activates RhoA and Cdc42) activated RhoG in vitro.	dbs	68-71	ras homolog family member G	Homo sapiens	115-119
12215546-7	2002	Supporting this conclusion, oncogenic Dbs activates endogenous RhoA but not endogenous Cdc42 in NIH 3T3 cells.	dbs	38-41	ras homolog family member A	Mus musculus	63-67
12215546-8	2002	Similarly, a competitive inhibitor that blocks RhoA activation also blocks Dbs-mediated transformation.	dbs	75-78	ras homolog family member A	Mus musculus	47-51
12215546-10	2002	These ideas are exemplified for Dbs, which is strongly implicated in the transformation of NIH 3T3 cells via RhoA and not Cdc42.	dbs	32-35	ras homolog family member A	Mus musculus	109-113
11577097-3	2001	Here we demonstrate that the conserved PH domains of three distinct Dbl family proteins, intersectin, Dbs, and Tiam1, selectively bind lipid vesicles only when phosphoinositides are present.	dbs	102-105	MCF.2 cell line derived transforming sequence	Homo sapiens	68-71
11889037-0	2002	A crystallographic view of interactions between Dbs and Cdc42: PH domain-assisted guanine nucleotide exchange.	dbs	48-51	cell division cycle 42	Homo sapiens	56-61
11889037-3	2002	In order to gain an understanding of the involvement of these PH domains in guanine nucleotide exchange, we have determined the crystal structure of a DH/PH fragment from Dbs in complex with Cdc42.	dbs	171-174	cell division cycle 42	Homo sapiens	191-196
11889037-5	2002	Consequently, the Dbs PH domain participates with the DH domain in binding Cdc42, primarily through a set of interactions involving switch 2 of the GTPase.	dbs	18-21	cell division cycle 42	Homo sapiens	75-80
11889037-6	2002	Comparative sequence analysis suggests that a subset of Dbl-family proteins will utilize their PH domains similarly to Dbs.	dbs	119-122	MCF.2 cell line derived transforming sequence	Homo sapiens	56-59
12215546-0	2002	RhoGEF specificity mutants implicate RhoA as a target for Dbs transforming activity.	dbs	58-61	Rho guanine nucleotide exchange factor (GEF) 28	Mus musculus	0-6
12215546-0	2002	RhoGEF specificity mutants implicate RhoA as a target for Dbs transforming activity.	dbs	58-61	ras homolog family member A	Mus musculus	37-41
12215546-1	2002	Dbs is a Rho-specific guanine nucleotide exchange factor (RhoGEF) that exhibits transforming activity when overexpressed in NIH 3T3 mouse fibroblasts.	dbs	0-3	Rho guanine nucleotide exchange factor (GEF) 28	Mus musculus	9-56
12215546-1	2002	Dbs is a Rho-specific guanine nucleotide exchange factor (RhoGEF) that exhibits transforming activity when overexpressed in NIH 3T3 mouse fibroblasts.	dbs	0-3	Rho guanine nucleotide exchange factor (GEF) 28	Mus musculus	58-64
12215546-6	2002	Guided by this information, we mutated Dbs to alter significantly its relative exchange activity for RhoA versus Cdc42 and show that the transformation potential of Dbs correlates with exchange on RhoA but not Cdc42.	dbs	39-42	ras homolog family member A	Mus musculus	101-105
12215546-6	2002	Guided by this information, we mutated Dbs to alter significantly its relative exchange activity for RhoA versus Cdc42 and show that the transformation potential of Dbs correlates with exchange on RhoA but not Cdc42.	dbs	39-42	cell division cycle 42	Mus musculus	113-118
12215546-6	2002	Guided by this information, we mutated Dbs to alter significantly its relative exchange activity for RhoA versus Cdc42 and show that the transformation potential of Dbs correlates with exchange on RhoA but not Cdc42.	dbs	39-42	ras homolog family member A	Mus musculus	197-201
12215546-6	2002	Guided by this information, we mutated Dbs to alter significantly its relative exchange activity for RhoA versus Cdc42 and show that the transformation potential of Dbs correlates with exchange on RhoA but not Cdc42.	dbs	165-168	ras homolog family member A	Mus musculus	101-105
12006984-3	2002	To rationalize this specificity, we have determined crystal structures of the conserved, catalytic fragments (Dbl and pleckstrin homology domains) of the exchange factors intersectin and Dbs in complex with their cognate GTPases, Cdc42 and RhoA, respectively.	dbs	187-190	MCF.2 cell line derived transforming sequence	Homo sapiens	110-113
12006984-3	2002	To rationalize this specificity, we have determined crystal structures of the conserved, catalytic fragments (Dbl and pleckstrin homology domains) of the exchange factors intersectin and Dbs in complex with their cognate GTPases, Cdc42 and RhoA, respectively.	dbs	187-190	cell division cycle 42	Homo sapiens	230-235
12006984-3	2002	To rationalize this specificity, we have determined crystal structures of the conserved, catalytic fragments (Dbl and pleckstrin homology domains) of the exchange factors intersectin and Dbs in complex with their cognate GTPases, Cdc42 and RhoA, respectively.	dbs	187-190	ras homolog family member A	Homo sapiens	240-244
11839748-6	2002	Clg contains Dbl/pleckstrin homology domains with substantial sequence homology to many Rho family activators, including the transforming Dbl and Dbs/Ost oncogenes.	dbs	146-149	pleckstrin homology domain containing, family G (with RhoGef domain) member 2	Mus musculus	0-3
10567407-8	1999	Cdx-2/3 binds to the TATA box and another AT-rich motif, designated as DBS, within an evolutionarily conserved proximal element of the Cdx-2/3 promoter.	dbs	71-74	caudal type homeobox 2	Mus musculus	0-5
11493738-4	2001	RESULTS: A new partial D, DBS, encoded by an RHD-RHcE(5)-RHD hybrid allele, was found.	dbs	26-29	Rh blood group D antigen	Homo sapiens	45-48
11493738-4	2001	RESULTS: A new partial D, DBS, encoded by an RHD-RHcE(5)-RHD hybrid allele, was found.	dbs	26-29	Rh blood group CcEe antigens	Homo sapiens	49-53
11493738-4	2001	RESULTS: A new partial D, DBS, encoded by an RHD-RHcE(5)-RHD hybrid allele, was found.	dbs	26-29	Rh blood group D antigen	Homo sapiens	57-60
11577097-6	2001	Likewise, GEF activity afforded by DH/PH fragments of intersectin and Dbs are also not altered by phosphoinositide interactions.	dbs	70-73	Rho/Rac guanine nucleotide exchange factor 2	Homo sapiens	10-13
10567407-8	1999	Cdx-2/3 binds to the TATA box and another AT-rich motif, designated as DBS, within an evolutionarily conserved proximal element of the Cdx-2/3 promoter.	dbs	71-74	caudal type homeobox 2	Mus musculus	135-140
10222100-2	1999	The amount of Cd2+ adsorbed depended strongly on the composition of the binary liquid; at an ethanol mole fraction of 0.05 (x1 = 0.05), 95% of the added Cd2+ is located in the ethanolic nanoreactor at the HDP-M (or DBS-C) surface.	dbs	215-218	CD2 molecule	Homo sapiens	14-17
10523665-0	1999	Dependence of Dbl and Dbs transformation on MEK and NF-kappaB activation.	dbs	22-25	mitogen-activated protein kinase kinase 7	Homo sapiens	44-47
10523665-0	1999	Dependence of Dbl and Dbs transformation on MEK and NF-kappaB activation.	dbs	22-25	nuclear factor kappa B subunit 1	Homo sapiens	52-61
10523665-1	1999	Dbs was identified initially as a transforming protein and is a member of the Dbl family of proteins (>20 mammalian members).	dbs	0-3	MCF.2 cell line derived transforming sequence	Homo sapiens	78-81
10523665-2	1999	Here we show that Dbs, like its rat homolog Ost and the closely related Dbl, exhibited guanine nucleotide exchange activity for the Rho family members RhoA and Cdc42, but not Rac1, in vitro.	dbs	18-21	MCF.2 cell line derived transforming sequence	Homo sapiens	72-75
10523665-2	1999	Here we show that Dbs, like its rat homolog Ost and the closely related Dbl, exhibited guanine nucleotide exchange activity for the Rho family members RhoA and Cdc42, but not Rac1, in vitro.	dbs	18-21	ras homolog family member A	Rattus norvegicus	151-155
10523665-2	1999	Here we show that Dbs, like its rat homolog Ost and the closely related Dbl, exhibited guanine nucleotide exchange activity for the Rho family members RhoA and Cdc42, but not Rac1, in vitro.	dbs	18-21	cell division cycle 42	Rattus norvegicus	160-165
10523665-3	1999	Dbs transforming activity was blocked by specific inhibitors of RhoA and Cdc42 function, demonstrating the importance of these small GTPases in Dbs-mediated growth deregulation.	dbs	0-3	ras homolog family member A	Homo sapiens	64-68
10523665-3	1999	Dbs transforming activity was blocked by specific inhibitors of RhoA and Cdc42 function, demonstrating the importance of these small GTPases in Dbs-mediated growth deregulation.	dbs	0-3	cell division cycle 42	Homo sapiens	73-78
10523665-6	1999	Both Dbs and Dbl activate multiple signaling pathways that include activation of the Elk-1, Jun, and NF-kappaB transcription factors and stimulation of transcription from the cyclin D1 promoter.	dbs	5-8	ETS transcription factor ELK1	Homo sapiens	85-90
10523665-6	1999	Both Dbs and Dbl activate multiple signaling pathways that include activation of the Elk-1, Jun, and NF-kappaB transcription factors and stimulation of transcription from the cyclin D1 promoter.	dbs	5-8	nuclear factor kappa B subunit 1	Homo sapiens	101-110
10523665-6	1999	Both Dbs and Dbl activate multiple signaling pathways that include activation of the Elk-1, Jun, and NF-kappaB transcription factors and stimulation of transcription from the cyclin D1 promoter.	dbs	5-8	cyclin D1	Homo sapiens	175-184
10523665-7	1999	We found that Elk-1 and NF-kappaB, but not Jun, activation was necessary for Dbl and Dbs transformation.	dbs	85-88	ETS transcription factor ELK1	Homo sapiens	14-19
10523665-7	1999	We found that Elk-1 and NF-kappaB, but not Jun, activation was necessary for Dbl and Dbs transformation.	dbs	85-88	nuclear factor kappa B subunit 1	Homo sapiens	24-33
10222100-3	1999	CdS nanoparticles have been generated in situ in ethanolic nanoreactors at the HDP-M and DBS-C surfaces.	dbs	89-92	CDP-diacylglycerol synthase 1	Homo sapiens	0-3
10222100-6	1999	X-ray diffractometry established that CdS nanoparticles stretched the HDP-M and DBS-C lamellas unevenly upon intercalation.	dbs	80-83	CDP-diacylglycerol synthase 1	Homo sapiens	38-41
8910315-5	1996	Thus Lbc, Lfc, and Lsc appear to represent a subgroup of Dbl-related proteins that function as highly specific GEFs toward Rho and can be distinguished from Dbl, Ost, and Dbs which are less specific and show GEF activity toward both Rho and Cdc42.	dbs	171-174	MCF.2 cell line derived transforming sequence	Homo sapiens	57-60
7862449-0	1995	Retroviral transduction and oncogenic selection of a cDNA encoding Dbs, a homolog of the Dbl guanine nucleotide exchange factor.	dbs	67-70	mcf.2 transforming sequence	Mus musculus	89-92
7862449-4	1995	The transforming cDNA encoded a protein, designated Dbs, which had a region of high sequence similarity to the Dbl proto-oncogene.	dbs	52-55	mcf.2 transforming sequence	Mus musculus	111-114
31521396-2	2020	METHODS: We followed up eight PD patients before and three years after STN DBS surgery.	dbs	75-78	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	71-74
34980610-4	2022	This protocol describes an original innovative multicentre international study aimed to assess safety and efficacy of aDBS vs cDBS using a new generation of DBS IPG in PD (AlphaDBS system by Newronika SpA, Milan, Italy).	dbs	157-160	surfactant protein A1	Homo sapiens	201-204
31521396-9	2020	Among PSG variables during STN DBS OFF, durations of N3 sleep (P=0.017) and REM sleep (P=0.041) were negatively correlated with UPDRS scores at post-operative 1st year.	dbs	31-34	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	27-30
31521396-11	2020	Similar results obtained while stimulator was OFF at the end of 1st year support the presence of microlesion effect after STN DBS, which is probably not long lasting.	dbs	126-129	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	122-125
32222721-3	2020	In this study, we assessed the efficacy of subthalamic nucleus deep brain stimulation (STN DBS) in Parkinson disease-associated camptocormia and explored some of its mechanisms.	dbs	91-94	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	87-90
32079672-4	2020	We searched PubMed for studies on genetically confirmed monogenic dystonia treated with GPi DBS documenting pre-surgical and post-surgical assessments using the Burke-Fahn-Marsden Dystonia Rating Scale Motor Score (BFMMS) and Burke-Fahn-Marsden Disability Score (BFMDS).	dbs	92-95	glucose-6-phosphate isomerase	Homo sapiens	88-91
32079672-10	2020	CONCLUSIONS: GPi DBS outcomes vary across monogenic dystonias.	dbs	17-20	glucose-6-phosphate isomerase	Homo sapiens	13-16
31922299-4	2020	METHODS: Two groups of patients with focal or segmental dystonia were included in the study: 6 patients with GPi-DBS and 8 without DBS (control group).	dbs	113-116	glucose-6-phosphate isomerase	Homo sapiens	109-112
31922299-7	2020	RESULTS: In patients with GPi-DBS (stimulation ON and OFF), activity at rest was reduced in a prefrontal network, and during the motor task, sensorimotor cortex activity was lower than in patients without DBS.	dbs	30-33	glucose-6-phosphate isomerase	Homo sapiens	26-29
31922299-8	2020	Within-group contrasts (tapping > rest) showed less extensive task-induced motor network activation in GPi-DBS patients than in non-DBS controls.	dbs	107-110	glucose-6-phosphate isomerase	Homo sapiens	103-106
32222721-17	2020	CONCLUSIONS STN DBS can improve Parkinson disease-associated camptocormia; STN DBS assisted with rehabilitation and psychological intervention appears to be more effective.	dbs	16-19	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	12-15
32222721-17	2020	CONCLUSIONS STN DBS can improve Parkinson disease-associated camptocormia; STN DBS assisted with rehabilitation and psychological intervention appears to be more effective.	dbs	79-82	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	75-78
31189385-13	2019	Multilobar epileptogenic zone (P = .001) and DBS of the ANT-DBS (P = .003) were found to be significant predictors of these events.	dbs	45-48	solute carrier family 25 member 6	Homo sapiens	56-59
31096058-2	2019	Recently we introduced a patient-adjustable reconfigurable coil technology that substantially reduced local SAR at tips of single isolated DBS leads during MRI at 1.5 T in 9 realistic patient models.	dbs	139-142	sarcosine dehydrogenase	Homo sapiens	108-111
31096058-6	2019	A simple surgical modification in trajectory of implanted leads was demonstrated to increase the SAR reduction efficiency of the rotating coil to >90% in a patient with a fully implanted bilateral DBS system.	dbs	200-203	sarcosine dehydrogenase	Homo sapiens	97-100
31349224-1	2019	Stimulating cholinergic neurons causes urinary incontinence after DBS of the Gpi.	dbs	66-69	glucose-6-phosphate isomerase	Homo sapiens	77-80
30894331-9	2019	The locations of the ablated region and active DBS contact corresponded well with the segmented Vim nucleus.	dbs	47-50	vimentin	Homo sapiens	96-99
31085730-0	2019	Reader response: DBS of the PSA and the VIM in essential tremor: A randomized, double-blind, crossover trial.	dbs	17-20	aminopeptidase puromycin sensitive	Homo sapiens	28-31
31275687-0	2019	Psychiatric and Behavioral Complications of GPi DBS in an Adolescent with Myoclonus Dystonia.	dbs	48-51	glucose-6-phosphate isomerase	Homo sapiens	44-47
31085731-0	2019	Author response: DBS of the PSA and the VIM in essential tremor: A randomized, double-blind, crossover trial.	dbs	17-20	aminopeptidase puromycin sensitive	Homo sapiens	28-31
31158945-3	2019	We compared the effectiveness of DBS in patients with the GNAL mutation compared to that in patients with DYT1 and DYT6 in a previous study.	dbs	33-36	G protein subunit alpha L	Homo sapiens	58-62
30897260-4	2019	METHODS: We adapted a commercially available enzyme-linked immunosorbent assay (ELISA) kit from MyBiosource for the quantitative determination of TRACP-5b levels in serum and plasma for use with DBS.	dbs	195-198	acid phosphatase 5, tartrate resistant	Homo sapiens	146-154
30897260-6	2019	RESULTS: Plasma and DBS TRACP-5b concentrations showed a linear relationship.	dbs	20-23	acid phosphatase 5, tartrate resistant	Homo sapiens	24-32
30800263-7	2019	Results: Both groups attained similar benefits in UPDRS part III from STN-DBS (GA 43.2 +- 14.1% vs. LA 46.8 +- 13.8% decrease, p=0.45; DBS on/Med off vs. DBS off/Med off) and no difference in reduction of levodopa equivalent doses (GA 47.56 +- 18.98% vs. LA 51.37 +- 31.73%, p=0.51) at the five-year follow-up.	dbs	74-77	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	70-73
30637283-1	2018	Background: DBS in the ventral intermediate nucleus (VIM) of the thalamus has been a revolutionary treatment for patients with essential tremor (ET) by reducing tremor.	dbs	12-15	vimentin	Homo sapiens	53-56
30573340-9	2019	Multilobar epileptogenic zone (p = 0.001) and DBS of the ANT-DBS (p = 0.003) were found to be significant predictors of these events.	dbs	46-49	solute carrier family 25 member 6	Homo sapiens	57-60
30464181-1	2018	Clinical benefits of pallidal deep brain stimulation (GPi DBS) in dystonia increase relatively slowly suggesting slow plastic processes in the motor network.	dbs	58-61	glucose-6-phosphate isomerase	Homo sapiens	54-57
30464181-4	2018	The acute effects of GPi DBS were associated with a shortening of the motor response whereas the grey matter of chronically treated patients with a better clinical outcome showed hypertrophy of the supplementary motor area and cerebellar vermis.	dbs	25-28	glucose-6-phosphate isomerase	Homo sapiens	21-24
30464181-6	2018	Importantly, good responders to GPi DBS showed a similar level of short-latency intracortical inhibition in the motor cortex as healthy controls whereas non-responders were unable to increase it.	dbs	36-39	glucose-6-phosphate isomerase	Homo sapiens	32-35
30637283-5	2018	Methods: This was a randomized, placebo-controlled trial for patients with VIM DBS for ET.	dbs	79-82	vimentin	Homo sapiens	75-78
30637283-11	2018	Conclusion: Alternating stimulation patterns on a weekly basis for ET patients with VIM DBS reduced habituation in this pilot study.	dbs	88-91	vimentin	Homo sapiens	84-87
30105131-7	2018	Mean seizures reduction reached 80.3% in group of patients with ANT DBS with two nonresponders and 91.2% in group of patients with lesions.	dbs	68-71	solute carrier family 25 member 6	Homo sapiens	64-67
30337863-8	2018	Results: After 4.9 years, STN DBS produced significant improvement in the UPDRS III total scores and subscores of tremor, rigidity, and bradykinesia in the "Off" medication state in the ART group, less improvement in the MT group, and the least improvement in the TDT group.	dbs	30-33	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	26-29
30337863-13	2018	Long-term STN DBS produced the best effects on bradykinesia/rigidity in the "Off" medication state and on tremor in the "On" and "Off" medication states.	dbs	14-17	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	10-13
30123518-9	2018	Dystonia did not improve significantly with botulinum toxin, levodopa or trihexyphenidyl, but has shown marked improvement since DBS implantation in the GPi.	dbs	129-132	glucose-6-phosphate isomerase	Homo sapiens	153-156
29986725-4	2018	METHODS: An ELISA was used to quantify HRP2 in patient sample DBS extracts before and after heat-based immune complex dissociation.	dbs	62-65	HDGF like 2	Homo sapiens	39-43
29408408-5	2018	The interactions of NTF and STN DBS treatments have not been studied before.	dbs	32-35	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	28-31
29887826-4	2018	We examined in detail the DBS electrode position and stimulation parameters in two patients with uncontrollable laughter during programming after STN-DBS surgery and illustrated the anatomical correlates of the acute mood changes with STN stimulation.	dbs	26-29	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	235-238
29887826-7	2018	In the first patient, the DBS lead was placed more inferiorly and medially within the STN.	dbs	26-29	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	86-89
29887826-12	2018	DBS programming with more dorsal and lateral contacts within the STN should be entertained to minimize the emotional side effects.	dbs	0-3	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	65-68
29659494-4	2018	The study included 22 patients who underwent STN DBS.	dbs	49-52	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	45-48
29659494-6	2018	The primary outcome was the change from baseline in the motor subscore of the Unified Parkinson Disease Rating Scale (UPDRS-III) 12 months after STN DBS.	dbs	149-152	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	145-148
29659494-15	2018	Our comparative study indicates that bilateral STN DBS is effective and can be used in patients with Parkinson disease with prior unilateral stereotactic destructive operations on subcortical structures.	dbs	51-54	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	47-50
29408408-7	2018	However, CDNF improved the effect of acute STN DBS on front limb use asymmetry at 2 and 3 weeks after CDNF injection.	dbs	47-50	cerebral dopamine neurotrophic factor	Homo sapiens	9-13
29408408-9	2018	The combination of CDNF and acute STN DBS had a favorable effect on striatal tyrosine hydroxylase.	dbs	38-41	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	34-37
29408408-10	2018	This study presents a novel additive beneficial effect of NTF and STN DBS, which might be explained by the interaction of DBS-induced endogenous NTFs and exogenously injected CDNF.	dbs	70-73	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	66-69
29408408-10	2018	This study presents a novel additive beneficial effect of NTF and STN DBS, which might be explained by the interaction of DBS-induced endogenous NTFs and exogenously injected CDNF.	dbs	70-73	cerebral dopamine neurotrophic factor	Homo sapiens	175-179
29408408-10	2018	This study presents a novel additive beneficial effect of NTF and STN DBS, which might be explained by the interaction of DBS-induced endogenous NTFs and exogenously injected CDNF.	dbs	122-125	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	66-69
29408408-10	2018	This study presents a novel additive beneficial effect of NTF and STN DBS, which might be explained by the interaction of DBS-induced endogenous NTFs and exogenously injected CDNF.	dbs	122-125	cerebral dopamine neurotrophic factor	Homo sapiens	175-179
29422851-4	2017	Findings: STN DBS not only alleviated PD symptoms but also the CH, and hence the CH treatment could be withdrawn.	dbs	14-17	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	10-13
28668776-0	2018	GNAO1-related movement disorder with life-threatening exacerbations: movement phenomenology and response to DBS.	dbs	108-111	G protein subunit alpha o1	Homo sapiens	0-5
29137852-11	2018	Understanding causes of GPi-DBS-induced speech changes can improve DBS programming.	dbs	28-31	glucose-6-phosphate isomerase	Homo sapiens	24-27
29246604-9	2017	RESULTS: Bilateral GPi DBS improved the BFMDRS total movement score by 65% at short-term follow-up and by 53% at long-term follow-up when compared to baseline scores.	dbs	23-26	glucose-6-phosphate isomerase	Homo sapiens	19-22
29246604-13	2017	CONCLUSION: Our results showed that bilateral GPi DBS in craniocervical dystonia is effective and safe.	dbs	50-53	glucose-6-phosphate isomerase	Homo sapiens	46-49
29397743-1	2018	We herein report a smart amphiphilic supramolecular complex ([MimA-EDA-MimA]@[DBS]2) with stimuli-responsive self-assembly, constructed by 3-(3-formyl-4-hydroxybenzyl)-1-methylimidazolium chloride (MimACl), sodium dodecyl benzene sulfonate (SDBS), and ethylenediamine (EDA).	dbs	78-81	MTSS I-BAR domain containing 1	Homo sapiens	62-66
29397743-1	2018	We herein report a smart amphiphilic supramolecular complex ([MimA-EDA-MimA]@[DBS]2) with stimuli-responsive self-assembly, constructed by 3-(3-formyl-4-hydroxybenzyl)-1-methylimidazolium chloride (MimACl), sodium dodecyl benzene sulfonate (SDBS), and ethylenediamine (EDA).	dbs	78-81	MTSS I-BAR domain containing 1	Homo sapiens	71-75
29397743-2	2018	The self-assembly of [MimA-EDA-MimA]@[DBS]2 shows triple-sensitivities in response to pH, concentration, and salt.	dbs	38-41	MTSS I-BAR domain containing 1	Homo sapiens	22-26
29397743-2	2018	The self-assembly of [MimA-EDA-MimA]@[DBS]2 shows triple-sensitivities in response to pH, concentration, and salt.	dbs	38-41	MTSS I-BAR domain containing 1	Homo sapiens	31-35
29397743-4	2018	Vesicles can gradually fuse into vesicle clusters and elongated assemblies with increasing concentration of [MimA-EDA-MimA]@[DBS]2.	dbs	125-128	MTSS I-BAR domain containing 1	Homo sapiens	109-113
29397743-4	2018	Vesicles can gradually fuse into vesicle clusters and elongated assemblies with increasing concentration of [MimA-EDA-MimA]@[DBS]2.	dbs	125-128	MTSS I-BAR domain containing 1	Homo sapiens	118-122
29422851-6	2017	Conclusions: The anatomical proximity of the medial STN and hypothalamus, their similar connectivity via the hyperdirect pathway, and the autonomic effects of STN DBS could explain symptom relief for both PD and CH.	dbs	163-166	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	159-162
29255409-12	2017	In conclusion, DBS at ANT increased relative right hemispheric activity and this was linked with emotional modulation of behavior.	dbs	15-18	solute carrier family 25 member 6	Homo sapiens	22-25
29180681-1	2017	Subthalamic nucleus deep brain stimulation (STN DBS) protects dopaminergic neurons of the substantia nigra pars compacta (SNpc) against 6-OHDA and MPTP.	dbs	48-51	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	44-47
28962937-3	2017	OBJECTIVES: This study aimed to enhance the technique to measure GUSB activity by reducing the amount of reagents and the size of the DBS, as well as to determine some biochemical parameters of enzyme of healthy individuals.	dbs	134-137	glucuronidase beta	Homo sapiens	65-69
28962937-4	2017	METHODS: The measurement of GUSB in 3 and 1.2mm DBS (with reagents reduced 2.5- and fourfold) was correlated and the precision of the technique was tested.	dbs	48-51	glucuronidase beta	Homo sapiens	28-32
30838301-0	2018	Failure of Sequential Pallidal and Motor Thalamus DBS for Rapid-Onset Dystonia-Parkinsonism (DYT12).	dbs	50-53	ATPase Na+/K+ transporting subunit alpha 3	Homo sapiens	93-98
29180681-9	2017	Whether STN DBS can be protective in other models of synucleinopathy is unknown.	dbs	12-15	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	8-11
28450385-6	2017	RESULTS: With use of the MS/MS GAA assay in DBS, 96% of the pseudodeficiency newborns and all of the Pompe disease carriers were well separated from the IOPD and LOPD newborns.	dbs	44-47	alpha glucosidase	Homo sapiens	31-34
29115994-4	2017	The Geneva Cocktail Phenotypic approach presents several advantages including the "in vivo" measure of different cytochromes and transporter P-gp activities, their simultaneous determination in a single test, avoiding the influence of variability over time on phenotyping results, the administration of low dose substrates, a limited sampling strategy with an analytical method developed on DBS analysis.	dbs	391-394	phosphoglycolate phosphatase	Homo sapiens	141-145
28529730-0	2017	Effect of low versus high frequency stimulation on freezing of gait and other axial symptoms in Parkinson patients with bilateral STN DBS: a mini-review.	dbs	134-137	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	130-133
28590521-8	2017	The GPi reemerged in the late 1990s as a major stereotactic target for DBS in dystonia and, recently, in Tourette syndrome.	dbs	71-74	glucose-6-phosphate isomerase	Homo sapiens	4-7
28590521-9	2017	Lately, lesioning of the GPI is being proposed to treat refractory status dystonicus or to treat DBS withdrawal syndrome in PD patients.	dbs	97-100	glucose-6-phosphate isomerase	Homo sapiens	25-28
28297686-4	2017	He experienced the successful tremor relief after unipolar DBS in the globus pallidus internus(GPi)with Vercise<sup>TM</sup> but complained of dysarthria.	dbs	59-62	glucose-6-phosphate isomerase	Homo sapiens	95-98
28081297-6	2017	RESULTS: A total of 19/19 fetal RHD genotyping with maternal DBS were consistent with the follow-up serological RhD test results after birth.	dbs	61-64	Rh blood group D antigen	Homo sapiens	32-35
28297686-10	2017	A fine current steering of Vercise<sup>TM</sup> DBS is very useful in both, the early and late phases of GPi-DBS for dystonic syndrome.	dbs	60-63	glucose-6-phosphate isomerase	Homo sapiens	117-120
27322347-11	2016	Both VNS and DBS-ANT represent an important adjunct in the therapeutic armamentarium.	dbs	13-16	solute carrier family 25 member 6	Homo sapiens	17-20
27984022-5	2017	Here we augment STN DBS by supplementing with a serotonin-norepinephrine reuptake inhibitor commonly prescribed for pain, duloxetine.	dbs	20-23	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	16-19
27984022-11	2017	It is possible that duloxetine augments STN DBS with a central and peripheral additive effect, though a synergistic mechanism has not been excluded.	dbs	44-47	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	40-43
27441097-4	2016	CASE REPORT: A 24-year-old male underwent left Gpi DBS for medically refractory HT.	dbs	51-54	glucose-6-phosphate isomerase	Homo sapiens	47-50
27987852-3	2017	The chemical structure of the composite CNCs/[PEP-MIM]DBS was characterized via FTIR, 13C NMR, TGA, XRD, etc.	dbs	54-57	T-box transcription factor 1	Homo sapiens	95-98
29456879-4	2017	Methods: Persons with Parkinson"s disease (PWP) who had undergone bilateral deep brain stimulation of the subthalamic nucleus (DBS-STN) provided spontaneous speech samples and then repeated portions of their monologue both on and off stimulation.	dbs	127-130	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	131-134
26611690-1	2016	BACKGROUND: Dystonia has been treated well using deep brain stimulation at the globus pallidus internus (GPi DBS).	dbs	109-112	glucose-6-phosphate isomerase	Homo sapiens	105-108
30363426-0	2016	Once STN DBS, Always STN DBS?-Clinical, Ethical, and Financial Reflections on Deep Brain Stimulation for Parkinson"s Disease.	dbs	9-12	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	5-8
30363426-0	2016	Once STN DBS, Always STN DBS?-Clinical, Ethical, and Financial Reflections on Deep Brain Stimulation for Parkinson"s Disease.	dbs	25-28	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	21-24
27375478-6	2016	CONCLUSIONS: The higher incidence of STN-DBS-related psychiatric complications underscores the need for comprehensive psychiatric pre- and postoperative assessment in older DBS candidates.	dbs	41-44	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	37-40
26611690-9	2016	CONCLUSIONS: The clinical outcome of phasic-type cervical dystonia is more favorable than that of tonic-type cervical dystonia following GPi DBS.	dbs	141-144	glucose-6-phosphate isomerase	Homo sapiens	137-140
26595680-3	2015	RESULTS: The feasibility of hepcidin (a peptide hormone) extraction and determination from DBS and VAMS blood sampling was investigated.	dbs	91-94	hepcidin antimicrobial peptide	Homo sapiens	28-36
28868498-6	2016	Its key feature is the ability to detect CRE and GAA in the same extract generated from neonatal DBS during amino acids (AA) and acylcarnitines (AC) analysis.	dbs	97-100	alpha glucosidase	Homo sapiens	49-52
28868498-8	2016	We describe an improved, non-derivatized DBS extraction and MS/MS analytical method (AAAC-GAMT) which incorporates quantitation of CRE and GAA into routine analysis of amino acids, acylcarnitines, and succinylacetone.	dbs	41-44	guanidinoacetate N-methyltransferase	Homo sapiens	90-94
28868498-8	2016	We describe an improved, non-derivatized DBS extraction and MS/MS analytical method (AAAC-GAMT) which incorporates quantitation of CRE and GAA into routine analysis of amino acids, acylcarnitines, and succinylacetone.	dbs	41-44	alpha glucosidase	Homo sapiens	139-142
26241157-10	2015	Multitarget DBS should be further explored in post-stroke dystonia and may offer improved outcome in other forms of secondary dystonia with limited response to GPi DBS.	dbs	12-15	glucose-6-phosphate isomerase	Homo sapiens	160-163
30363586-12	2016	Conclusions: This study confirms previous findings that verbal fluency declines after STN-DBS in PD patients in comparison to PD patients without DBS.	dbs	90-93	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	86-89
26089619-3	2015	Because of different in biological markers based on ethnicity, we aimed this study to validation a DBS-based fluorometric assay for measurement of alpha-l-Iduronidase activity for diagnosis of MPS I patients in Iran.	dbs	99-102	alpha-L-iduronidase	Homo sapiens	147-166
26002621-16	2015	The positive effects of GPi-DBS on the symptoms of spasmodic dysphonia merits further research as DBS is not commonly applied in this population.	dbs	28-31	glucose-6-phosphate isomerase	Homo sapiens	24-27
26225862-6	2015	Osteoblasts seeded on PPy-DBS or gold showed similar vinculin attachment points, vinculin area per cell area, actin filament structure, and Feret"s diameter, while cells seeded on PPY-CS or PPY-pTS showed disturbed focal adhesions and were enlarged with disorganized actin filaments.	dbs	26-29	vinculin	Homo sapiens	53-61
26225862-6	2015	Osteoblasts seeded on PPy-DBS or gold showed similar vinculin attachment points, vinculin area per cell area, actin filament structure, and Feret"s diameter, while cells seeded on PPY-CS or PPY-pTS showed disturbed focal adhesions and were enlarged with disorganized actin filaments.	dbs	26-29	vinculin	Homo sapiens	81-89
26225862-8	2015	In conclusion, PPy doped with DBS showed excellent biocompatibility, which resulted in maintaining focal adhesions, cell morphology, cell number, alkaline phosphatase activity, and osteocalcin gene expression.	dbs	30-33	bone gamma-carboxyglutamate protein	Homo sapiens	181-192
26089619-9	2015	Measurement of alpha-l-Iduronidase activity in DBS samples is an accurate test for diagnosis of MPS I and because of its rapid shipping and simplicity to keeping, DBS-based enzyme activity could be considered as a useful diagnostic tool in this disease.	dbs	47-50	alpha-L-iduronidase	Homo sapiens	15-34
26089619-9	2015	Measurement of alpha-l-Iduronidase activity in DBS samples is an accurate test for diagnosis of MPS I and because of its rapid shipping and simplicity to keeping, DBS-based enzyme activity could be considered as a useful diagnostic tool in this disease.	dbs	163-166	alpha-L-iduronidase	Homo sapiens	15-34
25909965-1	2015	Novel gemini supra-amphiphiles, [Mim-4-Mim][DBS](2) and [Mim-4-Mim][DS](2), were facilely constructed.	dbs	44-47	MTSS I-BAR domain containing 1	Homo sapiens	33-36
25909965-4	2015	Rich lamellar structures, including unilamellar and multilamellar vesicles, planar bilayers, and lamellar liquid crystals can be formed by [Mim-4-Mim][DBS](2), which is constructed through electrostatic and pi-pi stacking interactions.	dbs	151-154	MTSS I-BAR domain containing 1	Homo sapiens	140-143
25909965-4	2015	Rich lamellar structures, including unilamellar and multilamellar vesicles, planar bilayers, and lamellar liquid crystals can be formed by [Mim-4-Mim][DBS](2), which is constructed through electrostatic and pi-pi stacking interactions.	dbs	151-154	MTSS I-BAR domain containing 1	Homo sapiens	146-149
25909965-5	2015	With increasing temperatures, [Mim-4-Mim][DBS](2) exhibits interesting phase separation in the L(a) phase, behaving like common nonionic surfactants.	dbs	42-45	MTSS I-BAR domain containing 1	Homo sapiens	31-34
25909965-5	2015	With increasing temperatures, [Mim-4-Mim][DBS](2) exhibits interesting phase separation in the L(a) phase, behaving like common nonionic surfactants.	dbs	42-45	MTSS I-BAR domain containing 1	Homo sapiens	37-40
26090080-1	2015	Subthalamic deep brain stimulation (STN DBS) is an established treatment for the motor symptoms in patients with advanced Parkinson"s disease (PD).	dbs	40-43	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	36-39
26090080-2	2015	In addition to improvements in motor symptoms, many studies have reported changes in various nonmotor symptoms (NMSs) after STN DBS in patients with PD.	dbs	128-131	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	124-127
26090080-5	2015	Pain, especially PD-related pain, improves with STN DBS.	dbs	52-55	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	48-51
25802776-6	2015	GPi DBS should be considered in dystonic PKAN patients provided fixed contractures and/or pyramidal symptoms are not present.	dbs	4-7	glucose-6-phosphate isomerase	Homo sapiens	0-3
26056553-2	2015	Deep brain stimulation of bilateral subthalamic nucleus deep brain stimulation (STN DBS) has been shown to improve motor symptoms in PD and effects on NMS are unknown.	dbs	84-87	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	80-83
26056553-9	2015	RESULTS: Patients who underwent STN DBS had a significantly lower mean total score on NMS quest (6.7 +- 3.8) compared to controls (8.4 +- 3.7) (P < 0.00100).	dbs	36-39	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	32-35
26056553-12	2015	CONCLUSION: Bilateral STN DBS not only improves the motor symptoms but also improves many NMS in PD patients.	dbs	26-29	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	22-25
25653290-6	2015	Additional DBS of the same or another brain target was performed in 3 of 8 patients with DYT6 dystonia with varying results.	dbs	11-14	THAP domain containing 1	Homo sapiens	89-93
25653290-9	2015	However, the effect of DBS appears to be less predictable in patients with DYT6, suggesting that pre-DBS genetic testing and counseling for known dystonia gene mutations may be indicated.	dbs	23-26	THAP domain containing 1	Homo sapiens	75-79
25433076-15	2015	Activation of FFA1 by LCFA and presumably FFA3 by SCFA increased DBS via GLP-2 release, whereas FFA2 activation stimulated DBS via muscarinic and 5-HT4 receptor activation.	dbs	65-68	mast cell protease 10	Rattus norvegicus	73-78
26558134-10	2015	The impact of levodopa intake on vowel articulation changed with STN DBS: before surgery, levodopa impaired articulation, while it no longer had a negative effect after surgery.	dbs	69-72	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	65-68
26558134-12	2015	These results indicate that while STN DBS could lead to a direct deterioration in articulation, it may indirectly improve it by reducing the levodopa dose required to manage motor symptoms.	dbs	38-41	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	34-37
26558134-0	2015	Articulatory Changes in Vowel Production following STN DBS and Levodopa Intake in Parkinson"s Disease.	dbs	55-58	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	51-54
26558134-13	2015	These findings suggest that, with respect to speech production, STN DBS and levodopa intake cannot be investigated separately because the two are intrinsically linked.	dbs	68-71	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	64-67
28635789-2	2015	MATERIAL AND METHODS: The study included 54 patients, who underwent bilateral STN DBS from 2003 to 2012.	dbs	82-85	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	78-81
24423593-7	2014	CONCLUSION: Due to its low-invasiveness, simple sample collection and minimal sample preparation, DBS represents a suitable method to simultaneously monitor in vivo activities of P-gp and CYP.	dbs	98-101	ATP binding cassette subfamily B member 1	Homo sapiens	179-183
25684852-8	2014	The patient was successfully treated unilaterally with the STN DBS.	dbs	63-66	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	59-62
24384639-0	2014	DBS reduced hemichorea associated with a developmental venous anomaly and microbleeding in STN.	dbs	0-3	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	91-94
24423593-0	2014	Simultaneous LC-MS/MS quantification of P-glycoprotein and cytochrome P450 probe substrates and their metabolites in DBS and plasma.	dbs	117-120	ATP binding cassette subfamily B member 1	Homo sapiens	40-54
24423593-1	2014	BACKGROUND: An LC-MS/MS method has been developed for the simultaneous quantification of P-glycoprotein (P-gp) and cytochrome P450 (CYP) probe substrates and their Phase I metabolites in DBS and plasma.	dbs	187-190	ATP binding cassette subfamily B member 1	Homo sapiens	89-103
25167201-3	2014	We sought to analyze feasibility and reliability of alphaFP dosage using an analytical micromethod based on blood dried on filter paper (DBS).	dbs	137-140	alpha fetoprotein	Homo sapiens	52-59
25167201-5	2014	The plasma alphaFP dosage method was adapted to DBS adsorbed on paper matrix for newborn screening.	dbs	48-51	alpha fetoprotein	Homo sapiens	11-18
25167201-9	2014	CONCLUSION: The DBS method allowed to dose alphaFP reliably and consistently for the concentrations commonly employed in clinical settings for the screening of hepatoblastoma, opening new scenarios about conducting cancer screening in overgrowth syndromes.	dbs	16-19	alpha fetoprotein	Homo sapiens	43-50
25409685-14	2014	CONCLUSIONS: Considering that Pol theta is involved in DBS repair, our results suggest that this polymorphism may contribute to the etiology of HBC, particularly in patients with bilateral breast cancer.	dbs	55-58	keratin 88, pseudogene	Homo sapiens	144-147
25352821-1	2014	OBJECTIVES: To evaluate the effect of deep brain stimulation of the subthalamic nucleus (STN-DBS) on alexithymia, a deficit in affective regulation, comparing patients with Parkinson"s disease (PD) submitted to STN-DBS (DBS group) to PD patients not yet treated with STN-DBS (pre-DBS group) and to healthy participants (C group).	dbs	93-96	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	89-92
25352821-2	2014	METHODS: We recruited 27 consecutive STN-DBS PD patients, 38 consecutive pre-DBS patients and 27 healthy participants.	dbs	41-44	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	37-40
25352821-8	2014	CONCLUSION: Although the results suggest that STN-DBS does not affect alexithymia, both the DBS and pre-DBS patients reported higher prevalence (about 30%) of alexithymia than did healthy subjects (14.8%).	dbs	50-53	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	46-49
25023279-7	2014	In addition, silencing EphA2, PATJ, Src, or Dbs expression blocked LMW-HA-mediated RhoA activation.	dbs	44-47	ras homolog family member A	Homo sapiens	83-87
25023279-9	2014	Taken together, these results indicate LMW-HA-mediated transactivation of EphA2 is required for PATJ and Dbs membrane recruitment and subsequent RhoA activation required for angiogenesis.	dbs	105-108	EPH receptor A2	Homo sapiens	74-79
24240172-8	2014	Furthermore, Dbs, a guanine nucletotide exchange factor of RhoA much more enhanced GTP binding to RhoA complexed with RhoGDI in the presence of IKKgamma.	dbs	13-16	ras homolog family member A	Mus musculus	59-63
24240172-8	2014	Furthermore, Dbs, a guanine nucletotide exchange factor of RhoA much more enhanced GTP binding to RhoA complexed with RhoGDI in the presence of IKKgamma.	dbs	13-16	ras homolog family member A	Mus musculus	98-102
24240172-8	2014	Furthermore, Dbs, a guanine nucletotide exchange factor of RhoA much more enhanced GTP binding to RhoA complexed with RhoGDI in the presence of IKKgamma.	dbs	13-16	Rho GDP dissociation inhibitor (GDI) alpha	Mus musculus	118-124
24240172-8	2014	Furthermore, Dbs, a guanine nucletotide exchange factor of RhoA much more enhanced GTP binding to RhoA complexed with RhoGDI in the presence of IKKgamma.	dbs	13-16	inhibitor of kappaB kinase gamma	Mus musculus	144-152
25496254-6	2014	CONCLUSIONS: The method for the quantification of tamoxifen and (Z)-endoxifen in DBS collected on DMPK-A cards was successfully validated.	dbs	81-84	DM1 protein kinase	Homo sapiens	98-102
24423593-1	2014	BACKGROUND: An LC-MS/MS method has been developed for the simultaneous quantification of P-glycoprotein (P-gp) and cytochrome P450 (CYP) probe substrates and their Phase I metabolites in DBS and plasma.	dbs	187-190	ATP binding cassette subfamily B member 1	Homo sapiens	105-109
23975649-14	2013	CONCLUSIONS: VIM DBS may reduce severe, disabling tremor in patients with MS.	dbs	17-20	vimentin	Homo sapiens	13-16
25042504-4	2014	DBS STN was applied to 22 patients (mean age 53.2 years, mean disease duration 9,6 years).	dbs	0-3	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	4-7
25042504-10	2014	We demonstrated that DBS STN improved UPDRS II, III scores, reduced dyskinesias and motor fluctuations.	dbs	21-24	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	25-28
23756194-3	2013	METHOD: Primarily, alpha-galactosidase A (alpha-Gal A) activity was investigated on DBS in 1136 patients of both sexes who underwent dialysis for CRF in Turkey.	dbs	84-87	galactosidase alpha	Homo sapiens	19-40
23756194-3	2013	METHOD: Primarily, alpha-galactosidase A (alpha-Gal A) activity was investigated on DBS in 1136 patients of both sexes who underwent dialysis for CRF in Turkey.	dbs	84-87	galactosidase alpha	Homo sapiens	42-53
23611688-7	2013	Vim was targeted in four patients and three had unilateral procedure and one bilateral Vim DBS.	dbs	91-94	vimentin	Homo sapiens	0-3
23829466-0	2013	Update of the EBF recommendation for the use of DBS in regulated bioanalysis integrating the conclusions from the EBF DBS-microsampling consortium.	dbs	48-51	EBF transcription factor 1	Homo sapiens	14-17
23829466-0	2013	Update of the EBF recommendation for the use of DBS in regulated bioanalysis integrating the conclusions from the EBF DBS-microsampling consortium.	dbs	118-121	EBF transcription factor 1	Homo sapiens	14-17
24002026-7	2013	Moreover, increased expression of endogenous mature miR-27a in A549 cells affects DBS rejoining kinetics early after irradiation.	dbs	82-85	microRNA 27a	Homo sapiens	52-59
23611688-12	2013	We propose that the patients with DT with a mild dystonia should be considered for Vim DBS procedure and the coexistence of severe DT and dystonia may be successfully controlled by combined GPi and Vim DBS surgeries.	dbs	87-90	vimentin	Homo sapiens	83-86
23611688-7	2013	Vim was targeted in four patients and three had unilateral procedure and one bilateral Vim DBS.	dbs	91-94	vimentin	Homo sapiens	87-90
23611688-12	2013	We propose that the patients with DT with a mild dystonia should be considered for Vim DBS procedure and the coexistence of severe DT and dystonia may be successfully controlled by combined GPi and Vim DBS surgeries.	dbs	202-205	vimentin	Homo sapiens	198-201
23611688-8	2013	GPi was targeted in four patients with bilateral DBS procedure in every patient from this subgroup.	dbs	49-52	glucose-6-phosphate isomerase	Homo sapiens	0-3
23611688-10	2013	The best results for tremor control were observed in patients with Vim DBS but they had persisting mild dystonia.	dbs	71-74	vimentin	Homo sapiens	67-70
23611688-11	2013	Patients with GPi DBS had average DT improvement by approximately 50% but their dystonia symptoms were markedly improved.	dbs	18-21	glucose-6-phosphate isomerase	Homo sapiens	14-17
23776755-11	2013	CONCLUSION: STN DBS outcomes can be improved even years after implantation.	dbs	16-19	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	12-15
22673745-4	2012	Direct participation of residue 43 in GEF-catalyzed exchange was confirmed by the observation that mutation of this position to a threonine reduced GEF-catalyzed nucleotide exchange activity in vitro (Vav2, XPLN, GEFT, Dbl and Dbs) and greatly depressed RhoA and RhoC GTP-loading profiles in cell lysates.	dbs	227-230	Rho/Rac guanine nucleotide exchange factor 2	Homo sapiens	148-151
23094951-2	2013	MATERIALS AND METHODS: We recorded local field potentials from the DBS lead in the GPi of four patients (seven hemispheres) with secondary dystonia and from one patient (two hemispheres) with primary DYT3+ dystonia.	dbs	67-70	glucose-6-phosphate isomerase	Homo sapiens	83-86
23094951-5	2013	In DYT3+ dystonia, power in the alpha and beta bands, but not theta band, was attenuated during HF DBS in the GPe and in GPi, and attenuation was most prominent in the high beta band.	dbs	99-102	TATA-box binding protein associated factor 1	Homo sapiens	3-7
24246460-3	2013	for determining GBA activity in dried blood spots on filter paper (DBS).	dbs	67-70	glucosylceramidase beta	Homo sapiens	16-19
22673745-4	2012	Direct participation of residue 43 in GEF-catalyzed exchange was confirmed by the observation that mutation of this position to a threonine reduced GEF-catalyzed nucleotide exchange activity in vitro (Vav2, XPLN, GEFT, Dbl and Dbs) and greatly depressed RhoA and RhoC GTP-loading profiles in cell lysates.	dbs	227-230	Rho/Rac guanine nucleotide exchange factor 2	Homo sapiens	38-41
23401150-3	2013	Emerging reports suggest good response to DBS of the internal globus pallidus (GPi) and ventral intermediate nucleus (VIM) of the thalamus.	dbs	42-45	vimentin	Homo sapiens	118-121
23269227-6	2013	DBS was effective in reversing these evoked deficits in the infralimbic cortex and the mediodorsal thalamic nucleus of MAM-treated rats to levels similar to those observed in control animals.	dbs	0-3	alpha-2-macroglobulin	Rattus norvegicus	119-122
22906073-5	2012	This lysine residue is conserved in the active sites of the four human PYK isoenzymes, which were also found to be irreversibly inhibited by DBS.	dbs	141-144	phosphorylase kinase regulatory subunit alpha 2	Homo sapiens	71-74
22906073-6	2012	X-ray structures of PYK isoforms show structural differences at the DBS-binding pocket, and this covalent inhibitor of PYK provides a chemical scaffold for the design of new families of potentially isoform-specific irreversible inhibitors.	dbs	68-71	phosphorylase kinase regulatory subunit alpha 2	Homo sapiens	20-23
22906073-6	2012	X-ray structures of PYK isoforms show structural differences at the DBS-binding pocket, and this covalent inhibitor of PYK provides a chemical scaffold for the design of new families of potentially isoform-specific irreversible inhibitors.	dbs	68-71	phosphorylase kinase regulatory subunit alpha 2	Homo sapiens	119-122
22946911-0	2012	Updates from the EBF DBS--microsampling consortium.	dbs	21-24	EBF transcription factor 1	Homo sapiens	17-20
24868407-1	2012	The aim of this report was to describe a case of hypomania after deep brain stimulation of the subthalamic nucleus (STN DBS) in a Parkinson"s disease (PD) patient.	dbs	120-123	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	116-119
24868407-6	2012	Moreover, the anatomical location and the functional alteration of the STN after the DBS surgery might be related to the regulatory system of the associative and limbic cortico-subcortical circuits.	dbs	85-88	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	71-74
22673745-4	2012	Direct participation of residue 43 in GEF-catalyzed exchange was confirmed by the observation that mutation of this position to a threonine reduced GEF-catalyzed nucleotide exchange activity in vitro (Vav2, XPLN, GEFT, Dbl and Dbs) and greatly depressed RhoA and RhoC GTP-loading profiles in cell lysates.	dbs	227-230	ras homolog family member A	Homo sapiens	254-258
22673745-4	2012	Direct participation of residue 43 in GEF-catalyzed exchange was confirmed by the observation that mutation of this position to a threonine reduced GEF-catalyzed nucleotide exchange activity in vitro (Vav2, XPLN, GEFT, Dbl and Dbs) and greatly depressed RhoA and RhoC GTP-loading profiles in cell lysates.	dbs	227-230	ras homolog family member C	Homo sapiens	263-267
21597941-2	2011	The links between Stn DBS and advanced Parkinson disease, and between GPi DBS and dystonia are nearly universally accepted by the neurologists and neurosurgeons.	dbs	22-25	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	18-21
22060555-9	2011	ADSL activity in DBS was highly unstable, disqualifying DBS for diagnostic procedures.	dbs	17-20	adenylosuccinate lyase	Homo sapiens	0-4
22060555-9	2011	ADSL activity in DBS was highly unstable, disqualifying DBS for diagnostic procedures.	dbs	56-59	adenylosuccinate lyase	Homo sapiens	0-4
20403806-6	2010	These findings support the hypothesis that the formation of DBs in NDPK-A is involved in the regulation of the oligomerization and bioactivity of this multiple function protein, and that C145 is a key residue in the regulation of NDPK-A.	dbs	60-63	NME/NM23 nucleoside diphosphate kinase 1	Homo sapiens	67-73
22398977-4	2011	Unilateral STN DBS and staged bilateral STN DBS patients gained 3.9 +- 2.0 kg and 5.6 +- 2.1 kg versus their preoperative baseline weight (P < 0.001, respectively) while PD controls without DBS lost 0.8 +- 1.1 kg.	dbs	44-47	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	40-43
22398977-4	2011	Unilateral STN DBS and staged bilateral STN DBS patients gained 3.9 +- 2.0 kg and 5.6 +- 2.1 kg versus their preoperative baseline weight (P < 0.001, respectively) while PD controls without DBS lost 0.8 +- 1.1 kg.	dbs	44-47	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	40-43
22398977-5	2011	Although bilateral STN DBS patients gained 1.7 kg more than unilateral STN DBS patients at 2 years, this difference was not statistically significant (P = 0.885).	dbs	23-26	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	19-22
22398977-5	2011	Although bilateral STN DBS patients gained 1.7 kg more than unilateral STN DBS patients at 2 years, this difference was not statistically significant (P = 0.885).	dbs	75-78	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	71-74
21425341-0	2011	DYT 6--a novel THAP1 mutation with excellent effect on pallidal DBS.	dbs	64-67	THAP domain containing 1	Homo sapiens	0-5
21425341-0	2011	DYT 6--a novel THAP1 mutation with excellent effect on pallidal DBS.	dbs	64-67	THAP domain containing 1	Homo sapiens	15-20
20882302-8	2010	RESULTS: The average of the distance between the centers of the electrodes in the five levels estimated in the fused image of brain CT and MRI taken at least 6 months after STN DBS was 1.33 mm (0.1-5.8 mm).	dbs	177-180	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	173-176
20882302-11	2010	CONCLUSIONS: The results suggest that there was significant discrepancy between the centers of electrodes estimated by CT and MRI after STN DBS surgery.	dbs	140-143	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	136-139
22398977-1	2011	Unilateral and bilateral subthalamic nucleus deep brain stimulation (STN DBS) in Parkinson"s disease (PD) result in weight gain in the initial postoperative months, but little is known about the changes in weight following unilateral and staged bilateral STN DBS over longer time intervals.	dbs	73-76	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	69-72
22398977-4	2011	Unilateral STN DBS and staged bilateral STN DBS patients gained 3.9 +- 2.0 kg and 5.6 +- 2.1 kg versus their preoperative baseline weight (P < 0.001, respectively) while PD controls without DBS lost 0.8 +- 1.1 kg.	dbs	15-18	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	11-14
22291786-7	2011	Clinical results revealed low efficiency of STN DBS on PIGD.	dbs	48-51	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	44-47
22291786-8	2011	Preliminary results of simultaneous PPN and STN DBS are very promising.	dbs	48-51	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	44-47
21192662-5	2011	Analysis of DBS from 75 random human newborns showed IdS activities in the range of 4.8-16.2 (mean 9.1) mumol/(h L of blood), which were clearly distinguished from the activities measured for 14 MPS-II patients at 0.17-0.52 (mean 0.29) mumol/(h L of blood).	dbs	12-15	iduronate 2-sulfatase	Homo sapiens	53-56
20965153-4	2011	CHS-111 reduced the cellular levels of GTP-bound RhoA, membrane recruitment of Rho-associated protein kinase 1 and the downstream myosin light chain 2 phosphorylation, and attenuated the interaction between phosphatidylinositol 4-phosphate 5-kinase (PIP5K) and Arf6, whereas it only slightly inhibited the guanine nucleotide exchange activity of human Dbs (DH/PH) protein and did not affect the arfaptin binding to Arf6.	dbs	352-355	phosphatidylinositol-5-phosphate 4-kinase type 2 gamma	Homo sapiens	207-248
21384292-2	2011	The authors present a group of ET patients treated with deep brain stimulation of the ventral intermediate nucleus of the thalamus (Vim DBS).	dbs	136-139	vimentin	Homo sapiens	132-135
21384292-3	2011	The aim of the study was to evaluate the efficacy and safety of Vim DBS in the treatment of ET.	dbs	68-71	vimentin	Homo sapiens	64-67
21384292-4	2011	MATERIAL AND METHODS: Between 2006 and 2009, 8 female and 10 male ET patients were treated with Vim DBS.	dbs	100-103	vimentin	Homo sapiens	96-99
21384292-13	2011	Head tremor reduction was reported by 75% of patients in the bilateral Vim DBS subgroup and 50% of patients in the unilateral Vim DBS subgroup.	dbs	130-133	vimentin	Homo sapiens	126-129
21384292-15	2011	CONCLUSIONS: Vim DBS is a safe and effective method of ET treatment.	dbs	17-20	vimentin	Homo sapiens	13-16
21384292-16	2011	Vim DBS improves activities of daily living of ET patients.	dbs	4-7	vimentin	Homo sapiens	0-3
21225515-2	2010	Neuromodulation with deep brain stimulation of the thalamic nucleus ventralis intermedius (Vim DBS) is a well accepted method of neurosurgical treatment of tremor related to essential tremor or Parkinson disease.	dbs	95-98	vimentin	Homo sapiens	91-94
21225515-3	2010	Vim DBS is not widely used to control MS tremor.	dbs	4-7	vimentin	Homo sapiens	0-3
21225515-4	2010	MATERIAL AND METHODS: Five MS patients with tremor (3 females and 2 males) were treated with Vim DBS.	dbs	97-100	vimentin	Homo sapiens	93-96
21225515-16	2010	CONCLUSIONS: The study confirms the value and safety of Vim DBS for treatment of MS-related tremor.	dbs	60-63	vimentin	Homo sapiens	56-59
20164375-4	2010	The selective NHE3 inhibitor S1611 or genetic ablation of NHE3 significantly reduced fluid absorptive rates and increased DBS.	dbs	122-125	solute carrier family 9 (sodium/hydrogen exchanger), member 3	Mus musculus	14-18
20164375-5	2010	Slc26a6 (PAT1) or Slc26a3 (DRA) ablation reduced the S1611-induced DBS increase and reduced fluid absorptive rates, suggesting that the effect of S1611 or NHE3 ablation on HCO(3)(-) secretion may be an unmasking of Slc26a6- and Slc26a3-mediated Cl(-)/HCO(3)(-) exchange activity.	dbs	67-70	solute carrier family 26, member 3	Mus musculus	18-25
20347936-1	2010	Subthalamic nucleus deep brain stimulation (STN DBS) ameliorates motor symptoms of Parkinson"s disease, but the precise mechanism is still unknown.	dbs	48-51	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	44-47
20347936-2	2010	Here, using a large animal (pig) model of human STN DBS neurosurgery, we utilized fast-scan cyclic voltammetry in combination with a carbon-fiber microelectrode (CFM) implanted into the striatum to monitor dopamine release evoked by electrical stimulation at a human DBS electrode (Medtronic 3389) that was stereotactically implanted into the STN using MRI and electrophysiological guidance.	dbs	52-55	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	48-51
20347936-7	2010	Taken together, these results support a dopamine neuronal activation hypothesis suggesting that STN DBS evokes striatal dopamine release by stimulation of nigrostriatal dopaminergic neurons.	dbs	100-103	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	96-99
20164375-5	2010	Slc26a6 (PAT1) or Slc26a3 (DRA) ablation reduced the S1611-induced DBS increase and reduced fluid absorptive rates, suggesting that the effect of S1611 or NHE3 ablation on HCO(3)(-) secretion may be an unmasking of Slc26a6- and Slc26a3-mediated Cl(-)/HCO(3)(-) exchange activity.	dbs	67-70	solute carrier family 26, member 3	Mus musculus	27-30
20164375-4	2010	The selective NHE3 inhibitor S1611 or genetic ablation of NHE3 significantly reduced fluid absorptive rates and increased DBS.	dbs	122-125	solute carrier family 9 (sodium/hydrogen exchanger), member 3	Mus musculus	58-62
20164375-5	2010	Slc26a6 (PAT1) or Slc26a3 (DRA) ablation reduced the S1611-induced DBS increase and reduced fluid absorptive rates, suggesting that the effect of S1611 or NHE3 ablation on HCO(3)(-) secretion may be an unmasking of Slc26a6- and Slc26a3-mediated Cl(-)/HCO(3)(-) exchange activity.	dbs	67-70	solute carrier family 26, member 6	Mus musculus	0-7
20164375-5	2010	Slc26a6 (PAT1) or Slc26a3 (DRA) ablation reduced the S1611-induced DBS increase and reduced fluid absorptive rates, suggesting that the effect of S1611 or NHE3 ablation on HCO(3)(-) secretion may be an unmasking of Slc26a6- and Slc26a3-mediated Cl(-)/HCO(3)(-) exchange activity.	dbs	67-70	solute carrier family 26, member 6	Mus musculus	9-13
19926703-1	2010	BACKGROUND AND PURPOSE: The Vim and VPL are important target regions of the thalamus for DBS.	dbs	89-92	vimentin	Homo sapiens	28-31
18566505-5	2008	These results suggest that therapeutic DBS of the STN likely results in a functional block for many STN axons, although a subset of STN axons may also be activated at the stimulating frequency.	dbs	39-42	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	50-53
19642867-8	2009	Moreover, the catalytic domains of SopE and Dbs are efficacious GEFs for RhoC.	dbs	44-47	ras homolog family member C	Homo sapiens	73-77
19657734-8	2009	CFTR(inh)-172 reduced lubiprostone (10 microM)-induced DBS increase, whereas net Cl(-) output was also unchanged.	dbs	55-58	CF transmembrane conductance regulator	Rattus norvegicus	0-4
19657734-10	2009	Furthermore, lubiprostone-induced DBS was inhibited by EP4 receptor antagonist, not by an EP1/2 receptor antagonist or by indomethacin pretreatment.	dbs	34-37	prostaglandin E receptor 4	Rattus norvegicus	55-58
19657734-11	2009	CONCLUSIONS: In this first study of the effect of lubiprostone on intestinal ion secretion in vivo, lubiprostone stimulated CFTR-dependent DBS without changing net Cl(-) secretion.	dbs	139-142	CF transmembrane conductance regulator	Rattus norvegicus	124-128
18566505-5	2008	These results suggest that therapeutic DBS of the STN likely results in a functional block for many STN axons, although a subset of STN axons may also be activated at the stimulating frequency.	dbs	39-42	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	100-103
18566505-5	2008	These results suggest that therapeutic DBS of the STN likely results in a functional block for many STN axons, although a subset of STN axons may also be activated at the stimulating frequency.	dbs	39-42	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	100-103
16730897-1	2006	The electrochemical oxidation of anionic surfactants (sodium dodecyl benzene sulfonate, DBS) contained in simulated wastewater treated by three-dimensional electrode system with combined modified kaolin served as packed bed particle electrodes and Ti/Co/SnO(2)-Sb(2)O(3) anode was studied, the chemical oxygen demand (COD) removal of pollutants in the solutions was also investigated.	dbs	88-91	strawberry notch homolog 1	Homo sapiens	254-257
18723828-7	2008	Enhanced expression of LPA(2) or Dbs also results in senescence bypass in primary mouse embryo fibroblasts in the presence of wild-type p53, in a Rho GTPase-dependent manner.	dbs	33-36	transformation related protein 53, pseudogene	Mus musculus	136-139
17712844-1	2007	Inconsistent response in freezing of gait (FOG) with levodopa treatment or STN DBS makes the pathogenesis difficult to understand.	dbs	79-82	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	75-78
17712844-2	2007	We studied brain areas associated with the expression of STN DBS effect on parkinsonian motor deficits and FOG.	dbs	61-64	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	57-60
17712844-6	2007	The percentage improvement of mFOG and UPDRS motor scores by STN DBS during levodopa off period was calculated.	dbs	65-68	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	61-64
17712844-8	2007	During levodopa off period, STN DBS improved the UPDRS motor scores by 32.3% and the mFOG scores by 56.6%.	dbs	32-35	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	28-31
17712844-12	2007	In conclusion, dysfunction of different cerebral cortical areas limits the beneficial effects of DBS on parkinsonian motor deficits and FOG.	dbs	97-100	zinc finger protein, FOG family member 1	Homo sapiens	136-139
18421247-2	2008	We report on a case of acute general motor worsening induced by the ingestion of fluphenazine in a parkinsonian patient successfully treated with STN DBS.	dbs	150-153	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	146-149
18421247-5	2008	We suggest that residual striatal and extrastriatal dopaminergic pathways still play a paramount role in mediating central neurotrasmissions that may take part in STN DBS"s mechanism of action.	dbs	167-170	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	163-166
16203995-3	2005	We previously demonstrated that TrkC directly phosphorylates and activates Dbs, the guanine-nucleotide exchange factor (GEF) for Cdc42, to partially mediate Schwann cell migration.	dbs	75-78	neurotrophic receptor tyrosine kinase 3	Homo sapiens	32-36
16540561-3	2006	Dystrophin is depleted from these synapses in mice lacking both alphaDB and betaDB, and DBs are depleted from these synapses in mice lacking dystrophin.	dbs	88-91	dystrophin, muscular dystrophy	Mus musculus	141-151
16201754-5	2005	Deletion of the hydroxyl side chain of tyrosine 32 substantially increases the affinity of Cdc42 for intersectin, yet severely cripples interaction with Dbs, a normally potent exchange factor of Cdc42.	dbs	153-156	cell division cycle 42	Homo sapiens	195-200
16203995-3	2005	We previously demonstrated that TrkC directly phosphorylates and activates Dbs, the guanine-nucleotide exchange factor (GEF) for Cdc42, to partially mediate Schwann cell migration.	dbs	75-78	Rho/Rac guanine nucleotide exchange factor 2	Homo sapiens	120-123
16203995-3	2005	We previously demonstrated that TrkC directly phosphorylates and activates Dbs, the guanine-nucleotide exchange factor (GEF) for Cdc42, to partially mediate Schwann cell migration.	dbs	75-78	cell division cycle 42	Homo sapiens	129-134
15499081-9	2005	Dimethyl amiloride (0.1 mM), an inhibitor of the basolateral sodium-hydrogen exchanger 1, also inhibited CO(2)-augumented DBS, although S-3226, a specific inhibitor of apical sodium-hydrogen exchanger 3, did not.	dbs	122-125	solute carrier family 9 member A1	Rattus norvegicus	61-88
15905414-1	2005	The cystic fibrosis (CF) transmembrane conductance regulator (CFTR) plays a crucial role in mediating duodenal bicarbonate (HCO(3)(-)) secretion (DBS).	dbs	146-149	CF transmembrane conductance regulator	Rattus norvegicus	4-60
15905414-1	2005	The cystic fibrosis (CF) transmembrane conductance regulator (CFTR) plays a crucial role in mediating duodenal bicarbonate (HCO(3)(-)) secretion (DBS).	dbs	146-149	CF transmembrane conductance regulator	Rattus norvegicus	62-66
15905414-4	2005	To further test this hypothesis, we examined the effect of a novel, potent, and highly selective CFTR inhibitor, CFTR(inh)-172, on DBS and duodenal ulceration in rats.	dbs	131-134	CF transmembrane conductance regulator	Rattus norvegicus	113-117
15905414-7	2005	Superfusion of CFTR(inh)-172 (0.1-10 microM) over the duodenal mucosa had no effect on basal DBS but at 10 microM inhibited acid-induced DBS, suggesting that its effect was limited to CFTR activation.	dbs	137-140	CF transmembrane conductance regulator	Rattus norvegicus	15-19
15905414-10	2005	CFTR(inh)-172 acutely produces CFTR dysfunction in rodents for up to 24 h. CFTR inhibition reduces acid-induced DBS but also prevents duodenal ulcer formation, supporting our hypothesis that intracellular HCO(3)(-) may be an important protective mechanism for duodenal epithelial cells.	dbs	112-115	CF transmembrane conductance regulator	Rattus norvegicus	0-4
15897194-4	2005	Moreover, the beta3beta4 loop of the PH domain of P-Rex2 is the determinant for Rac1 recognition, as substitution of the beta3beta4 loop of the PH domain of Dbs (a RhoA- and Cdc42-specific GEF) with that of P-Rex2 confers Rac1-specific binding capability to the PH domain of Dbs.	dbs	157-160	phosphatidylinositol-3,4,5-trisphosphate dependent Rac exchange factor 2	Homo sapiens	50-56
15897194-4	2005	Moreover, the beta3beta4 loop of the PH domain of P-Rex2 is the determinant for Rac1 recognition, as substitution of the beta3beta4 loop of the PH domain of Dbs (a RhoA- and Cdc42-specific GEF) with that of P-Rex2 confers Rac1-specific binding capability to the PH domain of Dbs.	dbs	157-160	Rac family small GTPase 1	Homo sapiens	80-84
15897194-4	2005	Moreover, the beta3beta4 loop of the PH domain of P-Rex2 is the determinant for Rac1 recognition, as substitution of the beta3beta4 loop of the PH domain of Dbs (a RhoA- and Cdc42-specific GEF) with that of P-Rex2 confers Rac1-specific binding capability to the PH domain of Dbs.	dbs	157-160	cell division cycle 42	Homo sapiens	174-179
15897194-4	2005	Moreover, the beta3beta4 loop of the PH domain of P-Rex2 is the determinant for Rac1 recognition, as substitution of the beta3beta4 loop of the PH domain of Dbs (a RhoA- and Cdc42-specific GEF) with that of P-Rex2 confers Rac1-specific binding capability to the PH domain of Dbs.	dbs	157-160	Rho/Rac guanine nucleotide exchange factor 2	Homo sapiens	189-192
15897194-4	2005	Moreover, the beta3beta4 loop of the PH domain of P-Rex2 is the determinant for Rac1 recognition, as substitution of the beta3beta4 loop of the PH domain of Dbs (a RhoA- and Cdc42-specific GEF) with that of P-Rex2 confers Rac1-specific binding capability to the PH domain of Dbs.	dbs	157-160	phosphatidylinositol-3,4,5-trisphosphate dependent Rac exchange factor 2	Homo sapiens	207-213
15897194-4	2005	Moreover, the beta3beta4 loop of the PH domain of P-Rex2 is the determinant for Rac1 recognition, as substitution of the beta3beta4 loop of the PH domain of Dbs (a RhoA- and Cdc42-specific GEF) with that of P-Rex2 confers Rac1-specific binding capability to the PH domain of Dbs.	dbs	157-160	Rac family small GTPase 1	Homo sapiens	222-226
15897194-4	2005	Moreover, the beta3beta4 loop of the PH domain of P-Rex2 is the determinant for Rac1 recognition, as substitution of the beta3beta4 loop of the PH domain of Dbs (a RhoA- and Cdc42-specific GEF) with that of P-Rex2 confers Rac1-specific binding capability to the PH domain of Dbs.	dbs	275-278	phosphatidylinositol-3,4,5-trisphosphate dependent Rac exchange factor 2	Homo sapiens	50-56
15897194-4	2005	Moreover, the beta3beta4 loop of the PH domain of P-Rex2 is the determinant for Rac1 recognition, as substitution of the beta3beta4 loop of the PH domain of Dbs (a RhoA- and Cdc42-specific GEF) with that of P-Rex2 confers Rac1-specific binding capability to the PH domain of Dbs.	dbs	275-278	Rac family small GTPase 1	Homo sapiens	80-84